Aimei Health Technology Co., Ltd. — Form 8-K Summary
Reporting date: October 5, 2026. This current report concerns a one-month extension of the company’s deadline to complete its initial business combination; it does not provide operating results for a fiscal period.
Business context and material event
The company deposited $34,330.96 into its trust account for public shareholders to extend its business-combination deadline from October 6, 2026, to November 6, 2026. The filing describes this as the 23rd extension permitted under the company’s amended and restated articles of association. The contemplated business combination is with United Hydrogen.
Financial obligations and terms
- Aimei Investment Ltd. provided an unsecured promissory note with principal of $34,330.96 to fund the extension payment.
- The note bears no interest, and its principal is due upon consummation of the business combination.
- The payee may elect to convert all or part of the note into private units at $10.00 per unit immediately before the business-combination closing, subject to written notice at least two business days beforehand. Each unit consists of one ordinary share and a right to receive one-fifth of an ordinary share.
- The extension payment is stated to be the lesser of $80,000 for all outstanding public shares and $0.033 per outstanding public share for each monthly extension.
Other financial metrics and outlook
The filing does not provide revenue, profit, cash flow, margins, debt totals, liquidity measures, or financial guidance. It does not report a change in operating performance versus a comparable prior period.
Investor points to verify
- Whether the business combination with United Hydrogen is completed by the November 6, 2026 termination date or another extension is sought.
- Whether Aimei Investment Ltd. seeks to convert any portion of the note, and the resulting potential dilution.
- The complete promissory-note terms in Exhibit 10.1, which the filing says qualify its summary.